Therapeutic Advances in Respiratory Disease

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Sin, D. D.
Right arrow Articles by Man, S.F. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Therapeutic Advances in Respiratory Disease, Vol. 2, No. 2, 65-74 (2008)
DOI: 10.1177/1753465808088903
© 2008 SAGE Publications

Reviews

Review: Surfactant protein D: A lung specific biomarker in COPD?

Don D. Sin

The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, St Paul's Hospital, Room 368A, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada, dsin{at}mrl.ubc.ca

Payam S. Pahlavan

The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, St Paul's Hospital, Room 368A, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada

S.F. Paul Man

The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, St Paul's Hospital, Room 368A, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada

A major impediment in the development of novel drugs for chronic obstructive pulmonary disease (COPD) has been the scarcity of a well-validated, robust, and easily obtainable intermediate end point such as serum biomarkers. To date the best serum biomarkers in COPD have been non-speci"c pro-in"ammatory molecules synthesized largely by extra-pulmonary organs. In COPD, an ideal biomarker would be one that (1) was produced mostly in the lungs (and was reliably measurable in the peripheral circulation using commercially available kits), (2) changed with the clinical status of patients or with relevant exposures; and (3) had inherent functional attributes that suggested a possible causal role in the pathogenesis of the disease. In this paper, we review one promising systemic biomarker that ful"lls some of these criteria, surfactant protein D (SPD).

Key Words: Surfactant D • COPD • biomarker • pathogenesis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?